Ramón Fernández de Bobadilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramón Fernández de Bobadilla has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Javier Pagonabarraga
Movement Disorders Unit, Neurology Department, Hospital Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
12 shared publications- Jaime Kulisevsky
Movement Disorders Unit, Neurology Department, Sant Pau Hospital, Barcelona, Spain
11 shared publications - Berta Pascual-Sedano
Movement disorders Unit, Sant Pau Hospital, Barcelona, Spain
7 shared publications Saül Martínez-Horta
Movement Disorders Unit, Neurology Department, Hospital Sant Pau, Barcelona, Spain; Biomedical Research Institute (IIB-Sant Pau), Barcelona, Spain; Centro de Investigación en Red-Enfermedades Neurodegenerativas (CIBERNED), Spain
5 shared publications- Antonia Campolongo
Movement disorders Unit, Sant Pau Hospital, Barcelona, Spain
3 shared publications Frederic Sampedro
Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 1 March 2018
- Published by Elsevier in Neurología
- Vol. 33 (2) , 140
Addenbrooke's Cognitive Examination III: un test neuropsicológico útil para el cribado y la obtención de perfiles cognitivos
- 1 March 2018
- Published by Elsevier in Neurología
- Vol. 33 (2) , 140
Open AccessAddenbrooke's Cognitive Examination III: un test neuropsicológico útil para el cribado y la obtención de perfiles cognitivos
- 1 October 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 43, 73-77
Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS)
- 1 October 2017
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 43, 73-77
Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS)
- 1 November 2016
- Published by Elsevier in Neurología
- Vol. 31 (9) , 646-648
Validación de la versión española del Mini-Addenbrooke's Cognitive Examination para el cribado de demencias
- 1 November 2016
- Published by Elsevier in Neurología
- Vol. 31 (9) , 646-648
Validación de la versión española del Mini-Addenbrooke's Cognitive Examination para el cribado de demencias
- 11 October 2016
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 11 (5) , 1334-1342
Non-demented Parkinson’s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes
Apathy is a common but poorly understood neuropsychiatric disturbance in Parkinson’s disease (PD). In a recent study using event-related brain potentials we demonstrated impaired reward processing and compromised mesocortico-limbic pathways in PD patients with clinical symptoms of apathy. Here we aimed to further investigate the involvement of reward circuits in apathetic PD patients by assessing potential differences in brain structure. Using structural magnetic resonance imaging (MRI) and voxel-based morphometry (VBM) we quantified grey matter volume (GMV) in a sample of 18 non-demented and non-depressed PD patients with apathy, and 18 matched non-apathetic patients. Both groups were equivalent in terms of sociodemographic characteristics, disease stage, cognitive performance and L-Dopa equivalent daily dose. Apathetic patients showed significant GMV loss in cortical and subcortical brain structures. Various clusters of cortical GMV decrease were found in the parietal, lateral prefrontal cortex, and orbitofrontal cortex (OFC). The second largest cluster of GMV loss was located in the left nucleus accumbens (NAcc), a subcortical structure that is a key node of the human reward circuit. Isolated apathy in our sample is explained by the combined GMV loss in regions involved in executive functions, and cortical and subcortical structures of the mesolimbic reward pathway. The correlations observed between apathy and cognition suggests apathy as a marker of more widespread brain degeneration even in a sample of non-demented PD patients.
- 11 October 2016
- Published by Springer Nature in Brain Imaging and Behavior
- Vol. 11 (5) , 1334-1342
Non-demented Parkinson’s disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes
Apathy is a common but poorly understood neuropsychiatric disturbance in Parkinson’s disease (PD). In a recent study using event-related brain potentials we demonstrated impaired reward processing and compromised mesocortico-limbic pathways in PD patients with clinical symptoms of apathy. Here we aimed to further investigate the involvement of reward circuits in apathetic PD patients by assessing potential differences in brain structure. Using structural magnetic resonance imaging (MRI) and voxel-based morphometry (VBM) we quantified grey matter volume (GMV) in a sample of 18 non-demented and non-depressed PD patients with apathy, and 18 matched non-apathetic patients. Both groups were equivalent in terms of sociodemographic characteristics, disease stage, cognitive performance and L-Dopa equivalent daily dose. Apathetic patients showed significant GMV loss in cortical and subcortical brain structures. Various clusters of cortical GMV decrease were found in the parietal, lateral prefrontal cortex, and orbitofrontal cortex (OFC). The second largest cluster of GMV loss was located in the left nucleus accumbens (NAcc), a subcortical structure that is a key node of the human reward circuit. Isolated apathy in our sample is explained by the combined GMV loss in regions involved in executive functions, and cortical and subcortical structures of the mesolimbic reward pathway. The correlations observed between apathy and cognition suggests apathy as a marker of more widespread brain degeneration even in a sample of non-demented PD patients.
- 1 June 2016
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 41 (5-6) , 243-250
Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III
Background: Addenbrooke's Cognitive Examination III (ACE-III) is a cognitive test that has been validated for the diagnosis of cognitive disorders. The aim of this study was to provide normative data for the ACE-III for age, education and gender. Methods: The Spanish version of the ACE-III was administered to a group of 273 healthy subjects in a multicenter study in Spain. Correlation and determination coefficients for age, education and gender were estimated. The overlapping interval strategy and linear regression analyses were used to provide adjusted norms for demographic factors and to explore the potential influence of these factors in the performance of the test. Results: Age and education correlated significantly with the total score and with all the domains. Gender correlated only with the domains of attention and visuospatial skills. Norms for the total score and for cognitive domains (attention, memory, fluency, language, and visuospatial skills) are provided. Conclusion: This study confirms the influence of demographic factors (especially age and education) on the performance in the ACE-III and provides normative data for the Spanish version of the ACE-III.
- 1 June 2016
- Published by S. Karger AG in Dementia and Geriatric Cognitive Disorders
- Vol. 41 (5-6) , 243-250
Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III
Background: Addenbrooke's Cognitive Examination III (ACE-III) is a cognitive test that has been validated for the diagnosis of cognitive disorders. The aim of this study was to provide normative data for the ACE-III for age, education and gender. Methods: The Spanish version of the ACE-III was administered to a group of 273 healthy subjects in a multicenter study in Spain. Correlation and determination coefficients for age, education and gender were estimated. The overlapping interval strategy and linear regression analyses were used to provide adjusted norms for demographic factors and to explore the potential influence of these factors in the performance of the test. Results: Age and education correlated significantly with the total score and with all the domains. Gender correlated only with the domains of attention and visuospatial skills. Norms for the total score and for cognitive domains (attention, memory, fluency, language, and visuospatial skills) are provided. Conclusion: This study confirms the influence of demographic factors (especially age and education) on the performance in the ACE-III and provides normative data for the Spanish version of the ACE-III.
- 1 April 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 25, 58-64
Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease
- 1 April 2016
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 25, 58-64
Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease
- 11 December 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 361, 66-71
Parkinson's Disease—Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment
- 11 December 2015
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 361, 66-71
Parkinson's Disease—Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment
- 26 September 2015
- Published by Wiley in Movement Disorders
- Vol. 31 (1) , 45-52
Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase
Objectives: The description of minor hallucinatory phenomena (presence, passage hallucinations) has widened the spectrum of psychosis in Parkinson's disease (PD). Minor hallucinatory phenomena seem to antedate the development of more severe hallucinations. Early detection of minor hallucinations may be useful for screening patients with more severe endophenotypes. Motivated by the observation of “de novo,” drug‐naive PD patients reporting minor hallucinations, we aimed to prospectively identify “de novo” untreated PD patients experiencing hallucinatory phenomena, and to compare their clinico‐demographic characteristics with those of untreated PD patients without hallucinations and healthy controls.Methods: Screening and description of psychosis was assessed by the Movement Disorders Society Unified Parkinson's Disease Rating Scale—Part I and a structured interview covering all types of psychotic phenomena reported in PD. Clinical, neuropsychological, and demographic data of PD patients with and without psychotic phenomena were compared with those of age‐ and education‐matched healthy controls.Results: Fifty drug‐naive, “de novo” PD patients and 100 controls were prospectively included. Minor hallucinations were experienced in 42% (21 of 50) PD patients and 5% controls (P < 0.0001). Coexistence of passage and presence hallucinations was the most common finding. Unexpectedly, 33.3% of patients with minor hallucinations manifested these as a pre‐motor symptom, starting 7 months to 8 years before first parkinsonian motor symptoms. The presence of minor hallucinations was significantly associated with presence of rapid eye movement sleep behavior disorder.Conclusions: In this first study to prospectively analyze the frequency of minor hallucinatory phenomena in incident, untreated PD patients, hallucinations appeared as a frequent early non‐motor symptom that may even predate the onset of parkinsonism. © 2015 International Parkinson and Movement Disorder Society
- 26 September 2015
- Published by Wiley in Movement Disorders
- Vol. 31 (1) , 45-52
Minor hallucinations occur in drug‐naive Parkinson's disease patients, even from the premotor phase
Objectives: The description of minor hallucinatory phenomena (presence, passage hallucinations) has widened the spectrum of psychosis in Parkinson's disease (PD). Minor hallucinatory phenomena seem to antedate the development of more severe hallucinations. Early detection of minor hallucinations may be useful for screening patients with more severe endophenotypes. Motivated by the observation of “de novo,” drug‐naive PD patients reporting minor hallucinations, we aimed to prospectively identify “de novo” untreated PD patients experiencing hallucinatory phenomena, and to compare their clinico‐demographic characteristics with those of untreated PD patients without hallucinations and healthy controls.Methods: Screening and description of psychosis was assessed by the Movement Disorders Society Unified Parkinson's Disease Rating Scale—Part I and a structured interview covering all types of psychotic phenomena reported in PD. Clinical, neuropsychological, and demographic data of PD patients with and without psychotic phenomena were compared with those of age‐ and education‐matched healthy controls.Results: Fifty drug‐naive, “de novo” PD patients and 100 controls were prospectively included. Minor hallucinations were experienced in 42% (21 of 50) PD patients and 5% controls (P < 0.0001). Coexistence of passage and presence hallucinations was the most common finding. Unexpectedly, 33.3% of patients with minor hallucinations manifested these as a pre‐motor symptom, starting 7 months to 8 years before first parkinsonian motor symptoms. The presence of minor hallucinations was significantly associated with presence of rapid eye movement sleep behavior disorder.Conclusions: In this first study to prospectively analyze the frequency of minor hallucinatory phenomena in incident, untreated PD patients, hallucinations appeared as a frequent early non‐motor symptom that may even predate the onset of parkinsonism. © 2015 International Parkinson and Movement Disorder Society
- Open Access
- 31 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136786
Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis
Multiple sclerosis (MS) is a chronic central nervous system disorder characterized by white matter inflammation, demyelination and neurodegeneration. Although cognitive dysfunction is a common manifestation, it may go unnoticed in recently-diagnosed patients. Prior studies suggest MS patients develop compensatory mechanisms potentially involving enhanced performance monitoring. Here we assessed the performance monitoring system in early-stage MS patients using the error-related negativity (ERN), an event-related brain potential (ERP) observed following behavioral errors. Twenty-seven early-stage MS patients and 31 controls were neuropsychologically assessed. Electroencephalography recordings were obtained while participants performed: a) a stop task and b) an auditory oddball task. Behavior and ERP measures were assessed. No differences in performance were found between groups in most neuropsychological tests or in behavior or ERP components in the auditory oddball task. However, the amplitude of the ERN associated with stop errors in the stop task was significantly higher in patients. ERN amplitude correlated positively with scores on the Expanded Disability Status Scale and the Multiple Sclerosis Severity Score, and negatively with the time since last relapse. Patients showed higher neuronal recruitment in tasks involving performance monitoring. Results suggest the development of compensatory brain mechanisms in early-stage MS and reflect the sensitivity of the ERN to detect these changes.
- 31 August 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (8) , e0136786
Open AccessNeurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis
Multiple sclerosis (MS) is a chronic central nervous system disorder characterized by white matter inflammation, demyelination and neurodegeneration. Although cognitive dysfunction is a common manifestation, it may go unnoticed in recently-diagnosed patients. Prior studies suggest MS patients develop compensatory mechanisms potentially involving enhanced performance monitoring. Here we assessed the performance monitoring system in early-stage MS patients using the error-related negativity (ERN), an event-related brain potential (ERP) observed following behavioral errors. Twenty-seven early-stage MS patients and 31 controls were neuropsychologically assessed. Electroencephalography recordings were obtained while participants performed: a) a stop task and b) an auditory oddball task. Behavior and ERP measures were assessed. No differences in performance were found between groups in most neuropsychological tests or in behavior or ERP components in the auditory oddball task. However, the amplitude of the ERN associated with stop errors in the stop task was significantly higher in patients. ERN amplitude correlated positively with scores on the Expanded Disability Status Scale and the Multiple Sclerosis Severity Score, and negatively with the time since last relapse. Patients showed higher neuronal recruitment in tasks involving performance monitoring. Results suggest the development of compensatory brain mechanisms in early-stage MS and reflect the sensitivity of the ERN to detect these changes.